Inspire is a small implanted device that treats obstructive sleep apnea by electrically stimulating the hypoglossal nerve, the nerve that controls your tongue. Each time you breathe in during sleep, the device sends a mild electrical pulse that pushes your tongue forward and stiffens the surrounding muscles, keeping your airway open. It was approved by the FDA in 2014 and has become the leading surgical alternative for people who cannot tolerate CPAP.
Why the Airway Closes in the First Place
During sleep, the muscles that hold your upper airway open relax. For most people, that relaxation is harmless. But in people with obstructive sleep apnea, the throat is already narrower or more collapsible than average, and when those muscles lose tone, the airway partially or completely collapses. The tongue, in particular, tends to fall backward toward the throat wall. This collapse is what causes the repeated breathing pauses, oxygen drops, and fragmented sleep that define obstructive sleep apnea.1PubMed Central. Pharyngeal motor control and the pathogenesis of obstructive sleep apnea
CPAP, the standard first-line treatment, solves this by blowing pressurized air through a mask to physically splint the airway open. It works well when people use it consistently, but a significant number of patients find it intolerable. Common complaints include nasal irritation, claustrophobia, mask leak, dry mouth, and noise. Some people simply stop using it.2PubMed. What characterizes patients who are unable to tolerate continuous positive airway pressure (CPAP) treatment? Others discontinue over time because of cost or preference for a different approach.3PubMed Central. Factors Affecting Long-Term Compliance of CPAP Treatment–A Single Centre Experience And dropping CPAP is not a neutral decision: a large registry-based study found that people who stopped using CPAP had a roughly 74% higher risk of dying over a median follow-up period of about two and a half years.4PubMed. Factors influencing adherence to continuous positive airway pressure treatment in obstructive sleep apnea and mortality associated with treatment failure – a national registry-based cohort study Inspire exists because those patients still need effective treatment.
The Mechanism Behind the Stimulation
The hypoglossal nerve is the motor nerve that controls the genioglossus, the fan-shaped muscle that makes up most of your tongue. When this nerve fires, the tongue stiffens and moves forward, pulling tissue away from the back of the throat and widening the airway. Early animal and human studies showed that electrically stimulating this nerve reduces how easily the throat collapses, increases airflow, and can stop obstructive events without waking the person up.5PubMed Central. Electrical stimulation of the hypoglossal nerve: a potential therapy
Inspire takes advantage of this by delivering timed pulses synchronized to your breathing. A small pressure-sensing lead, placed between the muscles of the ribcage, detects when you start to inhale. That signal tells the implanted pulse generator to fire a stimulation pulse along a cuff electrode wrapped around a branch of the hypoglossal nerve under the chin. The stimulation happens at a level strong enough to keep the tongue forward but gentle enough not to wake you. Research on how varying the pulse width and amplitude affects the tongue muscle shows that at shorter pulse durations, the system can make finer adjustments to stimulation intensity, which helps with comfort.6PubMed Central. Hypoglossal nerve stimulation in a pig model for evaluation of genioglossus muscle force with different stimulation parameters
What the Surgery Involves
The implant procedure is done under general anesthesia and typically takes a couple of hours. It involves three small incisions: one under the chin, one on the upper chest, and one along the ribcage. The surgeon places a stimulation lead around the appropriate branch of the hypoglossal nerve, threads a sensing lead between the intercostal muscles to detect breathing effort, and connects both leads to an implantable pulse generator (about the size of a small matchbox) placed in a pocket under the skin of the upper chest. The surgery ends with intraoperative testing to confirm that the stimulation actually moves the tongue forward.7PubMed. Hypoglossal nerve stimulation with Inspire: An operative technique
Most patients go home the same day or the next morning. The device is not turned on immediately. You typically wait about a month for the surgical sites to heal. After that, the device is activated at a low setting, and you begin using a handheld remote to turn it on at bedtime and off in the morning. About three months after activation, you go in for a titration sleep study where a technician adjusts the stimulation settings while monitoring your sleep, similar to the way CPAP pressure is calibrated during a sleep study.8PubMed Central. Daytime polysomnography to perform titration for upper airway stimulation in patients with obstructive sleep apnea
Who Qualifies
Inspire is not designed to replace CPAP for everyone with sleep apnea. It is specifically intended for people who have tried CPAP (or a mandibular advancement device) and could not tolerate it or found it ineffective. The standard criteria require moderate-to-severe obstructive sleep apnea, with an apnea-hypopnea index between 15 and 65 events per hour, and a body mass index under 35 (some guidelines use a cutoff of 32).9PubMed. Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: Update on French practices and position paper of the SFRMS, SPLF and SFORL sleep medicine work-group
The BMI limit matters because excess tissue in the throat and neck makes it harder for tongue movement alone to open the airway. But the most important screening step is a procedure called drug-induced sleep endoscopy, or DISE. During DISE, you’re sedated and a doctor passes a thin camera through your nose to watch exactly where and how your airway collapses. Inspire works best when the primary pattern is the tongue falling backward into the airway (anterior-posterior collapse). If the airway closes in a side-to-side pattern at the level of the soft palate, the tongue protrusion that Inspire produces may not help much. The variable collapse patterns patients have are a major reason success rates differ across surgical centers.10PubMed Central. Predictors of success in hypoglossal nerve stimulator implantation for obstructive sleep apnea
How Well It Works
The most cited definition of success for Inspire is the Sher criteria: a reduction of at least 50% in the apnea-hypopnea index, with the final AHI dropping below 20 events per hour. Across multiple centers, roughly two-thirds of eligible patients meet this threshold.11Sleep and Breathing. Hypoglossal nerve stimulation long-term clinical outcomes: a systematic review and meta-analysis
In terms of raw numbers, a systematic review and meta-analysis found that the Inspire device reduced AHI by about 20 events per hour in the short term and about 16 events per hour over the long term. It also lowered the oxygen desaturation index by a similar magnitude.12PubMed. Hypoglossal nerve stimulation for obstructive sleep apnea in adults: An updated systematic review and meta-analysis An earlier meta-analysis showed the AHI improvement held steady out to five years, with a mean reduction still around 18 events per hour at the five-year mark.11Sleep and Breathing. Hypoglossal nerve stimulation long-term clinical outcomes: a systematic review and meta-analysis
Those numbers are meaningful, but it’s worth being clear about what they mean in practice. Someone with an AHI of 35 who drops to 15 has gone from severe apnea to the upper end of mild. That’s a real improvement, but it’s not a cure. Some patients achieve an AHI below 5, which is essentially normal. Others land somewhere in between. And about a third of implanted patients don’t meet the Sher criteria at all, meaning the device helps but doesn’t resolve their apnea to the degree hoped for.
What Patients Actually Notice
The changes patients report often matter more to them than the AHI number. At 48 months of follow-up, daytime sleepiness scores dropped significantly, and sleep-related quality of life improved. Among bed partners, 85% reported that snoring had become soft or nonexistent.13PubMed. Upper Airway Stimulation for Obstructive Sleep Apnea: Patient-Reported Outcomes after 48 Months of Follow-up For many couples, the snoring reduction alone is transformative. Multiple studies confirm that patients generally report feeling less sleepy during the day and sleeping more restfully overall.14PubMed. Upper airway stimulation therapy: A novel approach to managing obstructive sleep apnea
Adherence is one of Inspire’s strongest selling points compared to CPAP. Because the device operates automatically once you turn it on with the remote, there’s no mask to fight with, no hose to untangle, and no noise machine on the nightstand. People tend to use it more consistently than CPAP, which matters because treatment only works during the hours it’s actually in use.
Risks and Things That Can Go Wrong
Like any implanted device, Inspire carries surgical and mechanical risks. The most common complaint after surgery is temporary tongue discomfort or soreness at the stimulation site, which typically fades as the tissue adapts. In the pivotal 18-month study, two patients required neurostimulator repositioning because of a device-related problem, and no cases of lasting tongue weakness were reported.15Sleep. Upper Airway Stimulation for Obstructive Sleep Apnea: Durability of the Treatment Effect at 18 Months
Over longer timeframes, device failures do occur. A seven-year single-center review of 348 patients found that about 5% needed a revision surgery because of hardware malfunction. The most common failure was damage to the respiratory sensing lead, which accounted for about two-thirds of revision cases. Other issues included lead migration (where the electrode shifted away from the nerve) and pulse generator replacement.16ScienceDirect / American Journal of Otolaryngology. Upper airway stimulation device failure: A 7-year single center experience The average time between initial implant and revision was about two years. A 5% revision rate over seven years is not alarming for an implanted medical device, but it does mean a small number of patients will need a second operation.
Some patients also find the stimulation sensation itself uncomfortable, especially at the higher settings needed to keep the airway open. This is where the post-surgical titration process matters: finding the sweet spot between effectiveness and comfort can take multiple adjustments.
Inspire for Adolescents With Down Syndrome
One of the more striking expansions of Inspire’s use has been in adolescents with Down syndrome. Children and teens with Down syndrome have a very high rate of obstructive sleep apnea because of their characteristic facial and airway anatomy, including a relatively large tongue and smaller midface. Standard treatments like tonsillectomy and adenoidectomy often don’t resolve the apnea completely, and getting a teenager with intellectual disability to wear a CPAP mask every night is frequently unrealistic.
An early pilot study in six adolescents aged 12 to 18 showed AHI reductions of 56% to 85%, with four of the six achieving an AHI below 5 events per hour. The therapy was well tolerated, with nightly use averaging between about 6 and 10 hours.17JAMA Otolaryngology–Head & Neck Surgery. Hypoglossal Nerve Stimulation in Adolescents With Down Syndrome and Obstructive Sleep Apnea A larger follow-up study of 42 adolescents confirmed those results: roughly two-thirds met the response threshold of a 50% AHI decrease, and about 73% reached an AHI below 10 at 12 months. Quality-of-life scores improved substantially, and the average nightly use was nine hours. The reoperation rate was under 5%, and the most common complication was temporary tongue discomfort in about 12% of patients.18JAMA Otolaryngology–Head & Neck Surgery. Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea
A systematic review concluded that hypoglossal nerve stimulation holds genuine promise for this population, improving not only breathing metrics but also neurocognitive measures and quality of life.19PubMed. Advances in the Use of Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Persistent Obstructive Sleep Apnea-A Systematic Review The FDA granted a specific approval for this use in 2023, making it the first neurostimulation therapy approved for pediatric obstructive sleep apnea.
Cost and Insurance Coverage
Inspire is expensive. The device, surgery, and follow-up typically run in the range of $30,000 to $40,000 or more before insurance, depending on the center. That sticker price naturally raises the question of whether it’s worth the investment. A cost-effectiveness model based on the original STAR trial projected that Inspire would add about one quality-adjusted life year over a patient’s lifetime compared to no treatment, at an incremental cost of roughly $43,000. That works out to about $39,500 per quality-adjusted life year gained, which falls comfortably within the $50,000 to $100,000 threshold that health economists typically consider acceptable. The model also projected that Inspire substantially reduced the ten-year risk of heart attack, stroke, and motor vehicle collisions in untreated sleep apnea patients.20PubMed Central. Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial
A UK-based analysis reached a similar conclusion from the perspective of the National Health Service, estimating the cost per quality-adjusted life year at roughly £18,000, with about a 69% probability of being cost-effective at the NHS’s £30,000 per QALY threshold.21PubMed Central. Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective These models depend on the assumption that the AHI improvements seen in trials are maintained over time, which the five-year data so far supports.
Most major insurance plans in the U.S. now cover Inspire for patients who meet the standard criteria, including Medicare. Prior authorization is usually required, and the insurer will typically want documentation of CPAP failure before approving the procedure. Out-of-pocket costs depend heavily on your plan’s deductible and coinsurance structure.
What’s Next for Nerve Stimulation in Sleep Apnea
The current Inspire system stimulates one side of the hypoglossal nerve only. That means only one side of the tongue is being pushed forward, which works well enough for most qualifying patients but leaves room for improvement. A newer approach under investigation is bilateral stimulation, where both sides of the nerve are activated simultaneously. A clinical trial evaluating a novel bilateral device has been launched, with the goal of expanding the types of airway collapse patterns that nerve stimulation can address.22PubMed Central. Bilateral hypoglossal nerve stimulation for obstructive sleep apnea: a nonrandomized clinical trial If bilateral stimulation proves effective, it could open the door for patients who currently fail the DISE screening because of unfavorable collapse patterns.
Researchers are also working on reducing the device’s size, extending battery life, and refining which nerve fibers are stimulated. The hypoglossal nerve has branches that protrude the tongue forward and other branches that retract it, so selectively stimulating only the protrusor fibers is critical. Better electrode designs and stimulation algorithms could improve both efficacy and comfort. The technology has been in development for roughly three decades, but the pace of refinement has accelerated since FDA approval, with the current generation of the device (Inspire IV) already representing several iterations of improvement over the original implant.23Upper Airway Stimulation Therapy for Obstructive Sleep Apnea. The Future in Upper Airway Stimulation Therapy
Living With the Device Day to Day
People who have Inspire implanted often have practical questions that clinical papers don’t address directly. You can feel the pulse generator under the skin of your chest, similar to a pacemaker. It’s visible as a slight bulge in thin individuals. The remote control is simple: you press a button to turn therapy on when you go to bed and off when you wake up. There is a short delay (usually programmable) between when you activate the device and when stimulation begins, giving you time to fall asleep before the pulses start.
MRI compatibility is a common concern. The current-generation Inspire system is MRI-conditional, meaning scans can be done under specific conditions (certain magnet strengths, body regions, and device settings). Your implanting surgeon and the MRI facility need to coordinate before any scan. Airport security detectors can pick up the implant, so carrying your device identification card is standard advice. The battery in the pulse generator lasts roughly 11 years on average, after which a minor outpatient procedure replaces just the generator without disturbing the leads.
Exercise and physical activity are generally unrestricted after full recovery from surgery, though contact sports that could deliver a direct blow to the chest or neck deserve a conversation with your surgeon. Most patients report that they forget the device is there during the day. At night, the sensation of the tongue moving forward takes some getting used to, and a few people describe it as a mild tingling or tugging. The majority adapt within the first few weeks of use.